Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06122493
- Locations
- 🇨🇳
Ruijin hospital, Shanghai jiaotong university school of medicine, Shanghai, Shanghai, China
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1016
- Registration Number
- NCT06119581
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇦🇹Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 160
- Registration Number
- NCT06109402
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 42
- Registration Number
- NCT06110195
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06110572
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT06107868
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT06103864
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 272
- Registration Number
- NCT06102395
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.